Tirzepatide·Eli Lilly·Injectable pen

Zepbound

Zepbound is a once-weekly injectable tirzepatide pen manufactured by Eli Lilly, FDA-approved in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. As the weight-loss counterpart to Mounjaro, Zepbound contains the same dual GIP/GLP-1 receptor agonist but carries the explicit anti-obesity indication. In the SURMOUNT clinical trial program, Zepbound demonstrated the highest average weight loss of any FDA-approved weight management medication -- 20-25% of body weight. At Weight Method, Zepbound-equivalent tirzepatide treatment starts at $349/month.

2.5mg5mg7.5mg10mg12.5mg15mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Zepbound is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Zepbound (tirzepatide) is an FDA-approved GLP-1 medication for weight loss. In clinical trials, patients lost an average of 15-22% of their body weight. Weight Method offers Zepbound starting at $297/month with virtual consultations and direct shipping.

Key Fact

Zepbound (tirzepatide 2.5-15mg) received FDA approval for chronic weight management in November 2023. It is the weight-loss-specific version of Mounjaro. SURMOUNT-1: 22.5% average body weight loss at 15mg over 72 weeks.

Source: FDA approval data; SURMOUNT-1 Trial, NEJM 2022

How does this medication work?

Zepbound (tirzepatide) activates both GIP and GLP-1 receptors to suppress appetite, enhance fat metabolism, and slow digestion — achieving the highest weight loss of any approved medication.

Zepbound leverages tirzepatide's dual-agonist mechanism, simultaneously targeting GIP and GLP-1 receptors to suppress appetite, slow gastric emptying, enhance fat metabolism, and improve insulin sensitivity. The GLP-1 component reduces hunger and food intake by acting on the brain's satiety centers, while the GIP component improves how the body metabolizes and stores fat. Together, these two hormonal pathways create a more comprehensive metabolic effect than GLP-1-only medications. This dual action is the primary reason Zepbound has achieved the highest weight loss results ever recorded in anti-obesity medication trials.

What is it FDA-approved for?

FDA-approved for chronic weight management (2023) in adults with obesity or overweight plus a comorbidity. The first dual GIP/GLP-1 agonist approved specifically for weight loss.

Zepbound is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The SURMOUNT trial program -- one of the largest obesity drug development programs ever conducted -- provided the clinical evidence for this approval, demonstrating consistent and significant weight loss across diverse patient populations.

What are the key facts you should know?

Once-weekly injection, 2.5mg to 15mg dose range, SURMOUNT-1 showed 22.5% average weight loss, over 36% of participants lost 25%+, manufactured by Eli Lilly.

Zepbound is available in six dose strengths -- 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg -- administered once weekly via a pre-filled injectable pen. In SURMOUNT-1, participants on the 15mg dose lost an average of 22.5% of body weight (approximately 52 lbs) over 72 weeks, with over 36% of participants losing 25% or more. SURMOUNT-2, which studied patients with type 2 diabetes and obesity, showed 14.7% average weight loss at the highest dose. Zepbound received FDA approval in November 2023 and became commercially available in early 2024.

Why choose this treatment?

Zepbound holds the highest weight loss results of any FDA-approved anti-obesity medication, with over a third of trial participants losing 25% or more of body weight.

Zepbound is the strongest FDA-approved option for patients whose primary goal is maximum weight loss. No other approved anti-obesity medication has matched its clinical trial results: average weight loss exceeding 20% of body weight, with over a third of participants losing 25% or more. If you are looking for the most aggressive evidence-based weight loss treatment available, Zepbound is the leading candidate. Weight Method offers tirzepatide treatment at $349/month with a licensed provider, personalized dosing plan, ongoing monitoring, and free home delivery.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Zepbound and Mounjaro both contain the same active ingredient -- tirzepatide -- manufactured by Eli Lilly, but they are approved for different indications. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved specifically for chronic weight management. The dose strengths and escalation schedules are identical. Your Weight Method provider will prescribe the appropriate formulation based on your health profile and goals.

In the SURMOUNT-1 trial, participants on Zepbound 15mg lost an average of 22.5% of body weight -- approximately 52 lbs -- over 72 weeks. Over 36% of participants lost 25% or more of their body weight. These are the highest weight loss results achieved by any FDA-approved anti-obesity medication. Real-world results typically range from 20-25% of body weight over 12-18 months.

Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved for weight loss, but Zepbound has demonstrated superior weight loss in comparable trial populations: approximately 22.5% vs. 15% average body weight reduction. Zepbound's dual GIP/GLP-1 mechanism targets two metabolic pathways instead of one. However, both are highly effective, and your Weight Method provider will recommend the best option for your specific situation.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. In SURMOUNT trials, approximately 25-30% of participants experienced nausea, most commonly during dose escalation. Most side effects are mild to moderate and resolve within a few weeks. Serious but rare side effects include pancreatitis, gallbladder issues, and allergic reactions. Your provider will monitor you throughout treatment.

Weight Method offers tirzepatide treatment at $349/month with no insurance required. Retail pricing for brand-name Zepbound can exceed $1,000/month without insurance coverage. Weight Method's pricing includes your medication, licensed provider consultation, individualized dosing plan, ongoing check-ins, and free delivery to your door.

You may be eligible for Zepbound if you have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea. You must be 18 or older and not pregnant or breastfeeding. Take the Weight Method quiz to check your eligibility in under two minutes.

Yes. Many patients switch from semaglutide to tirzepatide to achieve greater weight loss or break through a plateau. Your Weight Method provider will manage the transition, typically starting at a lower tirzepatide dose (2.5mg) and escalating gradually. There is no mandatory washout period, and your provider will determine the optimal timing and starting dose based on your current treatment.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Zepbound

Zepbound Side EffectsZepbound ResultsZepbound Dosingtirzepatide Dosage Calculator

Generic Medication

Tirzepatide

Other Tirzepatide Brands

MounjaroTirzepatide

Compare Zepbound

Mounjaro vs ZepboundWegovy vs ZepboundOzempic vs Zepbound

Zepbound by State

Zepbound in AlabamaZepbound in AlaskaZepbound in ArizonaZepbound in ArkansasZepbound in CaliforniaZepbound in Colorado